Plant Name: Piper wightii
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| MGAM; | |
| TDP1; BLM; HSD17B1; AOX1; | |
| MET; ABL1; MAPK1; EGFR; | |
| CA2; CA12; CA9; CA1; CA3; CA14; CA7; CA5A; CA4; CA6; | |
| ESR1; ESR2; | |
| ESRRB; ESRRA; | |
| MAOA; ALDH2; | |
| HIF1A; TP53; NFKB1; | |
| EP300; KAT2B; | |
| ABCG2; | |
| SLCO1B3; SLCO1B1; | |
| RAB9A; LMNA; NPC1; XBP1; THPO; | |
| FASN; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Bromodomain | EP300 | Histone acetyltransferase p300 | Q09472 | CHEMBL3784 |
| Bromodomain | KAT2B | Histone acetyltransferase PCAF | Q92831 | CHEMBL5500 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Hydrolase | MGAM | Maltase-glucoamylase | O43451 | CHEMBL2074 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALDH2 | Aldehyde dehydrogenase | P05091 | CHEMBL1935 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | ABL1 | Tyrosine-protein kinase ABL | P00519 | CHEMBL1862 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transferase | FASN | Fatty acid synthase | P49327 | CHEMBL4158 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | XBP1 | X-box-binding protein 1 | P17861 | CHEMBL1741176 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.157E-11 | 3.150E-08 | BLM, CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9, EP300, ESR1, ESR2, ESRRA, ESRRB, TP53 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 4.022E-08 | 6.737E-05 | ESR1, ESR2, ESRRA, ESRRB, HSD17B1, NPC1 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.195E-07 | 2.078E-04 | CYP1A2, CYP2C19, CYP2C9 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.944E-07 | 2.078E-04 | CA2, CA4, CA9, EGFR, SLCO1B1, SLCO1B3, TSHR |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 7.254E-07 | 5.095E-04 | ABL1, CA2, CA7, EGFR, HIF1A, MAPK1, NPC1 |
| MF | GO:0005488; binding | GO:0000977; RNA polymerase II regulatory region sequence-specific DNA binding | 1.139E-06 | 6.704E-04 | EP300, ESR1, ESR2, ESRRA, ESRRB, HIF1A, KAT2B, NFKB1, TP53, XBP1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.309E-06 | 7.499E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.392E-06 | 1.132E-03 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 5.071E-06 | 2.008E-03 | ESR1, ESR2 |
| BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 1.224E-05 | 3.416E-03 | EGFR, ESRRB, HIF1A |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.324E-05 | 3.605E-03 | ABL1, BLM, EGFR, ESR1, MAPK1, NFKB1, NPC1 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.425E-05 | 3.785E-03 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0002376; immune system process | GO:0001922; B-1 B cell homeostasis | 1.519E-05 | 3.822E-03 | ABL1, HIF1A |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.519E-05 | 3.822E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0018076; N-terminal peptidyl-lysine acetylation | 1.519E-05 | 3.822E-03 | EP300, KAT2B |
| BP | GO:0002376; immune system process | GO:0045637; regulation of myeloid cell differentiation | 1.683E-05 | 4.149E-03 | CA2, EP300, ESRRA, HIF1A, KAT2B, THPO |
| BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 1.715E-05 | 4.149E-03 | ESRRB, HIF1A, KAT2B, NFKB1 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.933E-05 | 4.576E-03 | CYP1A2, CYP2C19, CYP2C9, ESR1, HSD17B1, NPC1 |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 1.924E-05 | 4.576E-03 | BLM, EP300, HIF1A, TP53 |
| BP | GO:0050896; response to stimulus | GO:0043627; response to estrogen | 2.273E-05 | 5.322E-03 | CA2, EP300, ESR1, MAPK1 |
| BP | GO:0009987; cellular process | GO:0006990; positive regulation of transcription from RNA polymerase II promoter involved in unfolded protein response | 3.034E-05 | 6.416E-03 | EP300, XBP1 |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 3.064E-05 | 6.416E-03 | ESR1, ESR2, ESRRA, ESRRB, KAT2B |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 3.034E-05 | 6.416E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.034E-05 | 6.416E-03 | CYP1A2, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.064E-05 | 6.416E-03 | AOX1, CYP1A2, CYP2C19, CYP2C9, TBXAS1 |
| MF | GO:0140110; transcription regulator activity | GO:0001228; transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding | 3.533E-05 | 7.123E-03 | EP300, ESR1, ESRRA, ESRRB, HIF1A, NFKB1, TP53 |
| BP | GO:0032502; developmental process | GO:0002009; morphogenesis of an epithelium | 4.067E-05 | 7.906E-03 | CA2, CA9, EGFR, ESR1, HIF1A, MET |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 4.741E-05 | 8.917E-03 | CYP1A2, EGFR, MAPK1 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.718E-24 | 8.097E-20 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.933E-18 | 2.129E-14 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 6.202E-17 | 2.701E-13 | CA1, CA12, CA2, CA3, CA4, CA5A, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.695E-23 | 2.967E-21 | CA12; CA1; CA3; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 2.181E-07 | 1.805E-05 | KAT2B; EP300; MAPK1; TP53; ESR1; HIF1A |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 3.558E-07 | 1.805E-05 | MAPK1; TP53; MET; HIF1A; EGFR |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 4.126E-07 | 1.805E-05 | CYP2C9; MAOA; CYP1A2; AOX1; CYP2C19 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.131E-06 | 5.327E-05 | ABL1; EP300; MAPK1; HIF1A; MET; TP53; EGFR; NFKB1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.475E-06 | 5.125E-05 | EP300; MAPK1; TP53; EGFR; NFKB1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.757E-06 | 5.125E-05 | ALDH2; MAOA; CYP1A2; AOX1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 5.198E-06 | 9.097E-05 | MAPK1; TP53; HIF1A; ESR1; MET; EGFR |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.551E-06 | 6.906E-05 | ABL1; EP300; MAPK1; TP53; MET; EGFR; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 3.041E-06 | 6.653E-05 | EP300; MAPK1; HIF1A; EGFR; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.329E-05 | 1.939E-04 | MAPK1; TP53; EGFR; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.329E-05 | 1.939E-04 | EP300; MAPK1; MET; HIF1A |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.778E-05 | 2.157E-04 | MAPK1; TP53; MET; EGFR |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.879E-05 | 2.157E-04 | MAPK1; ESR1; NFKB1; ESR2 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.985E-05 | 2.157E-04 | ABL1; MAPK1; TP53; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.778E-05 | 2.157E-04 | SLCO1B1; CA2; SLCO1B3; ABCG2 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 2.095E-05 | 2.157E-04 | EP300; MAPK1; MET; EGFR |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 8.455E-05 | 7.398E-04 | KAT2B; EP300; MAPK1; TP53; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 6.587E-05 | 6.067E-04 | MAPK1; ESR1; EGFR; ESR2 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.365E-04 | 1.013E-03 | ABL1; MAPK1; MET; EGFR; NFKB1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.064E-04 | 8.467E-04 | CYP2C9; MAOA; MAPK1; CYP2C19 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.390E-04 | 1.013E-03 | ABL1; MAPK1; TP53; NFKB1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 2.474E-04 | 1.532E-03 | KAT2B; XBP1; EP300; TP53; NFKB1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.872E-04 | 1.664E-03 | CYP2C9; MGAM; ALDH2; MAOA; FASN; HSD17B1; TBXAS1; CYP1A2; AOX1; CYP2C19 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.512E-04 | 1.532E-03 | LMNA; MAPK1; TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.065E-04 | 1.390E-03 | MAPK1; TP53; EGFR; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.948E-04 | 1.664E-03 | EP300; MAPK1; TP53; NFKB1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 2.036E-04 | 1.390E-03 | MAPK1; TP53; EGFR |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 9.989E-05 | 8.324E-04 | MAPK1; TP53; EGFR |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 8.805E-04 | 4.055E-03 | MAPK1; TP53; MET; EGFR; NFKB1 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.538E-04 | 1.532E-03 | MAPK1; TP53; EGFR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 3.945E-04 | 1.973E-03 | MAPK1; TP53; EGFR |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 9.456E-04 | 4.137E-03 | EP300; MAPK1; NFKB1; TSHR |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.488E-05 | 3.391E-04 | CYP2C9; CYP1A2; CYP2C19 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.432E-04 | 1.877E-03 | CYP2C9; TBXAS1; CYP2C19 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 9.256E-04 | 4.137E-03 | ABL1; MAPK1; EGFR |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 4.506E-04 | 2.190E-03 | MET; EGFR; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.348E-03 | 8.742E-03 | MAPK1; TP53; EGFR; NFKB1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.424E-03 | 5.797E-03 | MAPK1; HIF1A; EGFR |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.945E-04 | 1.973E-03 | CYP2C9; CYP1A2; AOX1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 3.945E-04 | 1.973E-03 | ABL1; MAPK1; NFKB1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 7.793E-04 | 3.686E-03 | CYP2C9; CYP1A2; CYP2C19 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.332E-03 | 8.742E-03 | MAPK1; TP53; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 3.322E-03 | 1.118E-02 | RAB9A; TP53; NFKB1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 2.559E-03 | 9.331E-03 | ABL1; EP300; TP53 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 3.120E-03 | 1.071E-02 | EP300; MAPK1; EGFR |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 2.739E-03 | 9.585E-03 | ABL1; MAPK1; MET |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 5.054E-03 | 1.608E-02 | THPO; AOX1; EP300 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 6.704E-03 | 2.012E-02 | EP300; MAPK1; NFKB1 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 7.024E-03 | 2.012E-02 | EP300; MAPK1; NFKB1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 7.243E-03 | 2.012E-02 | TP53; MET; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 9.918E-03 | 2.516E-02 | EP300; TP53; NFKB1 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 7.808E-03 | 2.102E-02 | EP300; TP53; NFKB1 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 9.918E-03 | 2.516E-02 | MAPK1; MET; EGFR |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.116E-02 | 2.663E-02 | MAPK1; MET; EGFR |
| hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 2.043E-02 | 4.256E-02 | THPO; MET; EGFR |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 2.081E-02 | 4.285E-02 | MAPK1; NFKB1 |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 2.043E-02 | 4.256E-02 | EP300; MAPK1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.711E-02 | 3.697E-02 | MAPK1; EGFR |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 2.440E-02 | 4.798E-02 | MAPK1; NFKB1 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.819E-02 | 3.882E-02 | TP53; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 6.992E-03 | 2.012E-02 | MAPK1; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 2.278E-02 | 4.530E-02 | MAPK1; NFKB1 |
| hsa04350 | TGF-beta signaling pathway_Homo sapiens_hsa04350 | 1.471E-02 | 3.343E-02 | EP300; MAPK1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 2.198E-02 | 4.422E-02 | MAPK1; NFKB1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 2.198E-02 | 4.422E-02 | MAPK1; NFKB1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 7.722E-03 | 2.102E-02 | MAPK1; HIF1A |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.126E-02 | 2.663E-02 | MAPK1; NFKB1 |
| hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 9.280E-03 | 2.424E-02 | EP300; MAPK1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.538E-02 | 3.407E-02 | TP53; NFKB1 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.606E-02 | 3.514E-02 | MAPK1; EGFR |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.126E-02 | 2.663E-02 | MAPK1; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.538E-02 | 3.407E-02 | MAPK1; NFKB1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.126E-02 | 2.663E-02 | CYP2C9; CYP1A2 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 6.992E-03 | 2.012E-02 | MAPK1; NFKB1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 8.226E-03 | 2.181E-02 | MAPK1; TP53 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 1.186E-02 | 2.766E-02 | MAPK1; NFKB1 |
| hsa04330 | Notch signaling pathway_Homo sapiens_hsa04330 | 5.004E-03 | 1.608E-02 | KAT2B; EP300 |
| hsa00280 | Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | 5.004E-03 | 1.608E-02 | ALDH2; AOX1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 7.231E-03 | 2.012E-02 | HSD17B1; CYP1A2 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 5.209E-03 | 1.628E-02 | MAOA; NFKB1 |
| hsa00330 | Arginine and proline metabolism_Homo sapiens_hsa00330 | 5.419E-03 | 1.664E-02 | ALDH2; MAOA |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.849E-03 | 7.192E-03 | MAPK1; TP53 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 1.603E-03 | 6.377E-03 | MAPK1; EGFR |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 2.688E-03 | 9.585E-03 | MAOA; AOX1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.162E-03 | 4.960E-03 | CA2; CA4 |
| hsa00340 | Histidine metabolism_Homo sapiens_hsa00340 | 1.266E-03 | 5.275E-03 | ALDH2; MAOA |
| hsa00750 | Vitamin B6 metabolism_Homo sapiens_hsa00750 | 1.313E-02 | 3.023E-02 | AOX1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.095E-02 | 2.663E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; ESRRA |
| A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | MGAM |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle disease | M60-M63 | MGAM |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ESRRA |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; EGFR; EGFR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Hyperglycemia | R73.9 | MGAM |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | MGAM |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | TBXAS1; ESRRA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ESRRA |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A; FASN |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | TBXAS1 |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9; EGFR |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | ABL1 |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ALDH2 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; FASN |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; EGFR; EGFR; EGFR; ESR1; ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; TBXAS1; MGAM |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | ABL1 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | ABL1; ABL1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | TBXAS1 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | TBXAS1 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | ABL1; EGFR |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; ALDH2 |
| NA: NA | Gram-positive bacterial infection | NA | FASN |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA |
| A00-B99: Certain infectious and parasitic diseases | Dengue fever | A90 | MGAM |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | MGAM |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| C00-D49: Neoplasms | Glioma | C71 | ABL1; EGFR; EGFR |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ABL1; ESR1 |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; EGFR; EGFR; EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR; ESR1 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; EGFR; EGFR |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| C00-D49: Neoplasms | Intestinal cancer | NA | ABL1 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; ESRRA |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Dramatic weight loss | R63.4 | FASN |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | MGAM |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; MET; CA9; ABL1; MAPK1; NFKB1; EGFR; ESR1; ESR1; CA1; FASN |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; MET; CA9; ABL1; MAPK1; EGFR |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | ABL1 |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| A00-B99: Certain infectious and parasitic diseases | Mycobacterium tuberculosis infection | A15-A19 | FASN |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR |
| N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | ABL1; EGFR; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | TBXAS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | ALDH2 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |